Page 10 - Sarepta News Today

Shares of Sarepta Therapeutics soared 29% premarket on Monday as a backing by the U.S. health regulators advisers increased the certainty of an accelerated approval for the companys gene therapy... | May 15, 2023

Monday May 15, 2023 Trading Desk: (312) 236-8907 TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 8:30ET Empire Manufacturing, Fed's Goolsbee speaks; 9:15ET Fed's Kashkari speaks; 5:00ET Fed's Cook speaks Fed’s Bostic speaks (7:30am, 8:45am, 2pm, 3pm) TODAY’S HIGHLIGHTS: President Biden to meet Tuesday with House Leader McCarthy on the debt

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. Natera wins $19 million US verdict from ArcherDX in cancer-detection patent case Genetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for in...

In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. Natera wins $19 million US verdict from ArcherDX in cancer-detection patent case Genetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for in...

Outside advisers to the Food and Drug Administration on Friday voted in favor of granting accelerated approval to Sarepta Therapeutics gene therapy to treat Duchenne muscular dystrophy. The... | May 12, 2023

Swiss National Bank lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 190,300 shares of the biotechnology company’s stock after selling 6,800 shares during the quarter. Swiss National Bank […]

Advisers to the U.S. Food and Drug Administration will discuss Sarepta Therapeutics Incs gene therapy for Duchenne muscular dystrophy at a closely-watched meeting on Friday, days after the agency... | May 12, 2023

WFO SHREVEPORT Warnings, Watches and Advisories for Sunday, May 7, 2023

Adeno-Associated Virus Vectors in Gene Therapy Market